# Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer

> **NCT07683013** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hyundai Bioscience Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Castration-Resistant Prostate Cancer (CRPC)

## Interventions

- **DRUG:** CP-PCA07
- **DRUG:** Enzalutamide 40 mg capsule

## Key facts

- **NCT ID:** NCT07683013
- **Lead sponsor:** Hyundai Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683013, "Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*